{
    "clinical_study": {
        "@rank": "134483", 
        "arm_group": [
            {
                "arm_group_label": "Single and multiple dose of RPX7009", 
                "arm_group_type": "Experimental", 
                "description": "Single and multiple dose of RPX7009"
            }, 
            {
                "arm_group_label": "Single and multiple dose of RPX2014", 
                "arm_group_type": "Experimental", 
                "description": "Single and multiple dose of RPX2014"
            }, 
            {
                "arm_group_label": "Normal Saline", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Single and multiple dose of normal saline"
            }, 
            {
                "arm_group_label": "Combination RPX7009 and RPX2014", 
                "arm_group_type": "Experimental", 
                "description": "Single and Multiple dose of Combination RPX7009 and RPX2014"
            }
        ], 
        "brief_summary": {
            "textblock": "RPX7009 (beta-lactamase inhibitor) is being studied in combination with a carbapenem\n      (RPX2014) to treat bacterial infections, including those due to multi-drug resistant\n      bacteria."
        }, 
        "brief_title": "Safety, Tolerability, Pharmacokinetics of Intravenous RPX2014 and RPX7009 in Healthy Adult Subjects", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Healthy Volunteers", 
            "Bacterial Infections"
        ], 
        "condition_browse": {
            "mesh_term": "Bacterial Infections"
        }, 
        "detailed_description": {
            "textblock": "The worldwide spread of resistance to antibiotics among Gram-negative bacteria, particularly\n      members of the ESKAPE group of pathogens, has resulted in a crisis in the treatment of\n      hospital acquired infections. In particular, the recent dissemination of a serine\n      carbapenemase (e.g., KPC) in Enterobacteriaceae in US hospitals now poses a considerable\n      threat to the carbapenems and other members of the beta-lactam class of antimicrobial\n      agents.\n\n      Rempex is developing a fixed combination antibiotic of a carbapenem (RPX2014) plus a new\n      beta-lactamase inhibitor (RPX7009) which has activity against serine beta-lactamases,\n      including KPC. This Phase 1 study will assess the safety, tolerability and pharmacokinetics\n      of intravenous RPX2014 and RPX7009, administered alone and in combination, in healthy adult\n      subjects."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Healthy adult males and females, 18 to 55 years of age (inclusive) at the time of\n             screening.\n\n          2. Body mass index (BMI) \u2265 18.5 and \u2264 29.9 (kg/m2) and weight between 55.0 and 100.0 kg\n             (inclusive).\n\n          3. Medically healthy with clinically insignificant screening results (e.g., laboratory\n             profiles, medical histories, ECGs, physical examination) as deemed by the PI.\n\n          4. Non-tobacco/nicotine-containing product users for a minimum of Dose Study 6 months\n             prior to Day 1.\n\n          5. Voluntarily consent to participate in the study.\n\n          6. Sexually abstinent or agree to use two approved methods of contraception.\n\n        Exclusion Criteria:\n\n          1. History or presence of significant cardiovascular, pulmonary, hepatic, renal,\n             hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological,\n             or psychiatric disease.\n\n          2. Positive urine drug/alcohol testing at screening or check-in (Day -1).\n\n          3. Positive testing for human immunodeficiency virus (HIV), hepatitis B surface antigen\n             (HBsAg), or hepatitis C antibodies (HCV).\n\n          4. History or presence of alcoholism or drug abuse within the 2 years prior to Day 1.\n\n          5. Use of any over-the-counter (OTC) medication, including herbal products and vitamins,\n             within the 7 days prior to Day 1. Up to 2 grams per day of acetaminophen is allowed\n             for acute events at the discretion of the PI.\n\n          6. Blood donation or significant blood loss (i.e., > 500 mL) within 56 days prior to Day\n             1.\n\n          7. Plasma donation within 7 days prior to Day 1.\n\n          8. Participation in another investigational clinical trial within 30 days prior to Day\n             1.\n\n          9. Subjects who have any abnormalities on laboratory values at screening or check-in\n             (Day -1)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "94", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01897779", 
            "org_study_id": "Rempex 501"
        }, 
        "intervention": [
            {
                "arm_group_label": "Single and multiple dose of RPX7009", 
                "description": "Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation in cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.", 
                "intervention_name": "RPX7009", 
                "intervention_type": "Drug", 
                "other_name": "(beta-lactamase inhibitor)"
            }, 
            {
                "arm_group_label": "Single and multiple dose of RPX2014", 
                "description": "Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation for cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.", 
                "intervention_name": "RPX2014", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Normal Saline", 
                "description": "Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation for cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Normal saline"
            }, 
            {
                "arm_group_label": "Combination RPX7009 and RPX2014", 
                "description": "Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation in cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.", 
                "intervention_name": "Combination RPX7009 and RPX2014", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 27, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Adelaide", 
                    "country": "Australia", 
                    "state": "South Australia", 
                    "zip": "5000"
                }, 
                "name": "CMAX"
            }
        }, 
        "location_countries": {
            "country": "Australia"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous RPX2014 and RPX7009 Alone and in Combination in Healthy Adult Subjects", 
        "overall_official": {
            "affiliation": "Sponsor GmbH", 
            "last_name": "Jeffery Loutit", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Number of patients with adverse events; assessed by patient reporting, collection of vital signs, ECGs and absolute values and changes over time of hematology, chemistry and urinalysis.", 
            "measure": "Safety from baseline through the end of the study", 
            "safety_issue": "No", 
            "time_frame": "Study Day 1 to Day 14"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01897779"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Plasma AUC0-t, AUC0-inf, Cmax, and Tmax.", 
            "measure": "Composite of PK parameters RPX7009, RPX2014, combination of RPX7009 and RPX2014 & placebo following single and multiple dose administration.", 
            "safety_issue": "No", 
            "time_frame": "Study Day1 to Day 14"
        }, 
        "source": "Rempex Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Rempex Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}